TNX-601 ER for Depression
(UPLIFT Trial)
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
How is the drug TNX-601 ER different from other depression treatments?
TNX-601 ER is unique because it may involve a mechanism similar to traxoprodil, which targets specific brain pathways (BDNF/ERK/CREB and AKT/FOXO/Bim) for rapid and long-lasting antidepressant effects. This approach is different from traditional antidepressants, which often take longer to show effects.12345
What is the purpose of this trial?
This trial is testing a medication called TNX-601 ER to see if it can help people with depression by improving their mood through changes in brain chemicals.
Research Team
Gregory Sullivan, MD
Principal Investigator
Tonix Pharmaceuticals
Eligibility Criteria
Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either TNX-601 ER or placebo for 6 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Placebo
- TNX-601 ER
Find a Clinic Near You
Who Is Running the Clinical Trial?
Tonix Pharmaceuticals, Inc.
Lead Sponsor
Rho, Inc.
Industry Sponsor